Interim results from the phase II COCOON trial show a targeted strategy to reduce dermatologic toxicity in EGFR-mutant frontline NSCLC. The study, led by Bishal Tiwari of Nassau University Medical Center, tested a proactive skincare regimen and reported a 50% reduction in dermatologic adverse events. The trial focuses on managing the skin toxicities that frequently drive dose modifications and treatment interruptions for EGFR inhibitors. COCOON’s interim findings add evidence for protocolized prevention that could be incorporated into routine oncology care pathways pending final readouts.